- Home
- BGLC vs APM Comparison
BGLC vs APM Comparison
Compare BGLC & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- APM
- Stock Information
- Founded
- BGLC 2017
- APM 2010
- Country
- BGLC Malaysia
- APM United Kingdom
- Employees
- BGLC N/A
- APM N/A
- Industry
- BGLC Medical Specialities
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- APM Health Care
- Exchange
- BGLC Nasdaq
- APM Nasdaq
- Market Cap
- BGLC 5.8M
- APM 6.7M
- IPO Year
- BGLC N/A
- APM 2018
- Fundamental
- Price
- BGLC $0.29
- APM $0.83
- Analyst Decision
- BGLC
- APM
- Analyst Count
- BGLC 0
- APM 0
- Target Price
- BGLC N/A
- APM N/A
- AVG Volume (30 Days)
- BGLC 1.4M
- APM 27.7K
- Earning Date
- BGLC 05-14-2025
- APM 04-29-2025
- Dividend Yield
- BGLC N/A
- APM N/A
- EPS Growth
- BGLC N/A
- APM N/A
- EPS
- BGLC N/A
- APM 0.00
- Revenue
- BGLC $9,259,858.00
- APM N/A
- Revenue This Year
- BGLC N/A
- APM $157,729.10
- Revenue Next Year
- BGLC N/A
- APM N/A
- P/E Ratio
- BGLC N/A
- APM $248.07
- Revenue Growth
- BGLC N/A
- APM N/A
- 52 Week Low
- BGLC $0.21
- APM $0.46
- 52 Week High
- BGLC $1.00
- APM $11.19
- Technical
- Relative Strength Index (RSI)
- BGLC 45.41
- APM 38.15
- Support Level
- BGLC $0.23
- APM $0.80
- Resistance Level
- BGLC $0.29
- APM $0.88
- Average True Range (ATR)
- BGLC 0.03
- APM 0.06
- MACD
- BGLC -0.00
- APM 0.00
- Stochastic Oscillator
- BGLC 47.67
- APM 14.65
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.